ACRX - AcelRx Pharmaceuticals, Inc. Stock Price and Quote

ACRX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	0.11	EPS (ttm)	6.21	Insider Own	0.30%	Shs Outstand	7.38M	Perf Week	-2.76%
Market Cap	5.40M	Forward P/E	-	EPS next Y	-2.93	Insider Trans	0.00%	Shs Float	7.36M	Perf Month	-46.97%
Income	47.00M	PEG	-	EPS next Q	-0.51	Inst Own	12.40%	Short Float / Ratio	9.43% / 2.85	Perf Quarter	-64.65%
Sales	1.50M	P/S	3.60	EPS this Y	38.20%	Inst Trans	6.34%	Short Interest	0.69M	Perf Half Y	-83.88%
Book/sh	3.69	P/B	0.19	EPS next Y	-142.20%	ROA	72.70%	Target Price	80.00	Perf Year	-87.47%
Cash/sh	2.06	P/C	0.34	EPS next 5Y	-	ROE	-	52W Range	0.57 - 7.60	Perf YTD	-69.03%
Dividend	-	P/FCF	-	EPS past 5Y	21.00%	ROI	162.80%	52W High	-90.79%	Beta	0.36
Dividend %	-	Quick Ratio	1.50	Sales past 5Y	-30.50%	Gross Margin	-	52W Low	23.09%	ATR	0.12
Employees	43	Current Ratio	1.60	Sales Q/Q	-73.70%	Oper. Margin	-	RSI (14)	28.30	Volatility	12.82% 15.31%
Optionable	Yes	Debt/Eq	0.29	EPS Q/Q	33.10%	Profit Margin	-	Rel Volume	1.50	Prev Close	0.72
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 30 AMC	Payout	0.00%	Avg Volume	243.73K	Price	0.70
Recom	2.50	SMA20	-23.24%	SMA50	-52.29%	SMA200	-78.87%	Volume	362,864	Change	-2.78%

Jul-20-20

Downgrade

Credit Suisse

Neutral → Underperform

Nov-11-19

Downgrade

Credit Suisse

Outperform → Neutral

$7 → $2

Aug-05-19

Resumed

Credit Suisse

Outperform

Jul-10-19

Resumed

Credit Suisse

Outperform

Apr-24-19

Resumed

B. Riley FBR

Buy

$6.50

Feb-15-19

Initiated

Credit Suisse

Outperform

Oct-23-18

Initiated

B. Riley FBR

Buy

Oct-13-17

Reiterated

RBC Capital Mkts

Outperform

$6 → $5

Oct-13-17

Downgrade

Jefferies

Buy → Hold

Jul-14-17

Resumed

Jefferies

Buy

Show Previous Ratings

Mar-30-23 06:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 Insider Monkey
Mar-21-23 04:05PM	AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 PR Newswire +18.10%
Mar-14-23 08:30AM	AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals PR Newswire -21.05%
08:30AM	Loading…
Mar-01-23 08:30AM	AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures PR Newswire -7.04%
Dec-29-22 06:02AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript Insider Monkey +7.58%
Dec-27-22 08:30AM	AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock PR Newswire
Dec-19-22 08:17AM	10 Cheapest Stocks With Biggest Upside Insider Monkey -7.95%
Dec-08-22 08:30AM	AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine PR Newswire
Nov-17-22 05:17AM	AcelRx Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag Simply Wall St.
Nov-14-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates Zacks +17.96%
04:01PM	AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
Nov-03-22 08:30AM	AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022 PR Newswire
Oct-31-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 PR Newswire
08:30AM	Loading…
Oct-27-22 08:30AM	AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant PR Newswire -12.47%
Oct-26-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022 PR Newswire -12.81%
Oct-25-22 04:42PM	AcelRx Pharmaceuticals Announces Reverse Stock Split PR Newswire
08:30AM	AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences PR Newswire
Sep-06-22 04:30PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference PR Newswire -7.32%
Aug-25-22 08:30AM	AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting PR Newswire
Aug-11-22 05:35PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates Zacks +33.02%
04:01PM	AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
08:30AM	AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022 PR Newswire
Aug-10-22 08:30AM	AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting PR Newswire
Jul-28-22 04:50PM	AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022 PR Newswire
Jul-08-22 06:28AM	AcelRx Pharmaceuticals (NASDAQ:ACRX) shareholders are up 44% this past week, but still in the red over the last three years Simply Wall St. -13.71%
May-20-22 12:49PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference PR Newswire -11.83%
May-19-22 11:56AM	Why AcelRx Pharma Shares Are Trading Higher Today? Benzinga +27.63%
08:30AM	AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® PR Newswire
08:45AM	Loading…
May-16-22 08:45AM	AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:30AM	AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
May-12-22 05:35PM	Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates Zacks
May-10-22 05:35PM	Organogenesis (ORGO) Q1 Earnings Lag Estimates Zacks
08:30AM	AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia PR Newswire
May-09-22 07:30PM	AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022 PR Newswire -13.47%
Apr-27-22 08:00AM	AcelRx Hosting Key Opinion Leader Webinar on Niyad Nafamostat Program GlobeNewswire
Apr-25-22 08:30AM	Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022 PR Newswire
Apr-21-22 08:30AM	AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022 PR Newswire -8.00%
Mar-31-22 04:10PM	AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures PR Newswire
Mar-29-22 01:08PM	AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit PR Newswire -6.87%
Mar-10-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:01PM	AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results PR Newswire
Mar-03-22 04:05PM	AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022 PR Newswire -7.14%
Feb-01-22 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures PR Newswire
Jan-31-22 04:24AM	When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven? Simply Wall St. +11.77%
Jan-27-22 01:38PM	Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ... GuruFocus.com -8.64%
08:30AM	AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures PR Newswire
Jan-12-22 08:30AM	AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery PR Newswire -5.53%
Jan-10-22 08:30AM	AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics PR Newswire
Dec-23-21 08:05AM	Femasys Inc. to Participate in Upcoming January Investor Conferences GlobeNewswire
Dec-15-21 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery PR Newswire
Dec-01-21 07:12PM	Penny Stocks to Buy Using Technical Analysis for December 2021 Investopedia
Nov-23-21 05:09PM	AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors PR Newswire -5.22%
Nov-15-21 06:45AM	AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering PR Newswire -6.08%
06:00AM	AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results PR Newswire
Nov-10-21 08:30AM	AcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on November 15, 2021 PR Newswire
Nov-02-21 06:22AM	Investors in AcelRx Pharmaceuticals (NASDAQ:ACRX) have unfortunately lost 80% over the last three years Simply Wall St.
Oct-28-21 03:06PM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-21-21 09:32PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Provention Bio, Danimer Scientific, AcelRX, and Piedmont Lithium on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Oct-04-21 07:30AM	Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors GlobeNewswire
Sep-10-21 03:19PM	AcelRx Pharmaceuticals to Participate in Two September Investor Conferences PR Newswire
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) ACCESSWIRE
08:30AM	Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event PR Newswire
Aug-26-21 08:30AM	Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event PR Newswire
Aug-19-21 07:07AM	21 Stocks Moving in Thursday's Pre-Market Session Benzinga
Aug-16-21 05:25PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM	AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results PR Newswire
Aug-12-21 04:01PM	Moore Kuehn, PLLC Encourages Investors of ACRX to Contact Law Firm Newsfile
Aug-09-21 04:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX PR Newswire
01:30PM	ACRX Last Few Hours to Deadline: Shareholders With Losses Exceeding $50K in AcelRx Pharmaceuticals, Inc. Are Encouraged to Contact Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
10:16AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
10:00AM	ACRX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021 Newsfile
09:25AM	ACRX Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX Newsfile
08:30AM	AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021 PR Newswire
12:20AM	LEAD PLAINTIFF DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Aug-08-21 01:00PM	ACRX Final Deadline Tomorrow: Shareholders With Losses Exceeding $50K in AcelRx Pharmaceuticals, Inc. Should Contact Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Aug-07-21 02:35PM	ACRX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action ACRX GlobeNewswire
Aug-06-21 09:33PM	AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm GlobeNewswire
07:15PM	ACRX Final Deadline Monday: Rosen, a Trusted and Leading Law Firm, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX Newsfile
02:30PM	ACRX Monday Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders With Losses Exceeding $50K of Class Action ACCESSWIRE
01:03PM	DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
01:00PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:15PM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX) Business Wire
10:00AM	ACRX Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021 GlobeNewswire
Aug-05-21 11:25AM	MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
Aug-04-21 08:00PM	Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Rocket, 360 DigiTech, and Piedmont Lithium and Encourages Investors to Contact the Firm GlobeNewswire
12:00PM	FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors with LARGE LOSSES to Secure Counsel Before Final August 9 Deadline in Securities Class Action ACRX ACCESSWIRE
11:20AM	MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
11:05AM	DEADLINE ALERT for ACRX and RLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM	ACRX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021 Newsfile
01:17AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Is Expected To Breakeven In The Near Future Simply Wall St.
Aug-03-21 10:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX PR Newswire
12:00PM	Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX) GlobeNewswire
11:18AM	MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
Aug-02-21 10:24PM	ROSEN, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action ACRX Business Wire
03:01PM	Will AcelRx Pharmaceuticals (ACRX) Report Negative Q2 Earnings? What You Should Know Zacks
01:05PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:30PM	DEADLINE ALERT for ACRX, RLX, HPMT: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:00AM	ACRX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Investors of Class Action and Lead Plaintiff Deadline: August 9, 2021 Business Wire

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Angotti Vincent J.	Chief Executive Officer	Jun 07	Buy	0.22	46,400	10,333	1,016,919	Jun 08 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience